Going back to class I: MHC and immunotherapies for childhood cancer

    loading  Checking for direct PDF access through Ovid


After decades of unfulfilled promise, immunotherapies for cancer have reached a tipping point, with several FDA approved products now on the market and many more showing promise in both adult and pediatric clinical trials. Tumor cell expression of MHC class I has emerged as a potential determinant of the therapeutic success of many immunotherapy approaches. Here we review current knowledge regarding MHC class I expression in pediatric cancers including a discussion of prognostic significance, the opposing influence of MHC on T-cell versus NK-mediated therapies, and strategies to reverse or circumvent MHC down-regulation.Pediatr Blood Cancer 2015;62:571–576. © 2014 The Authors. Pediatric Blood & Cancer published by Wiley Periodicals, Inc.

    loading  Loading Related Articles